“Engage” Therapy: Behavioral Activation and Improvement of Late-Life Major Depression

Objective Engage is a treatment for late-life depression developed to match the skills of community clinicians based on the theory that dysfunction in the Research Domain Criteria Project positive valence systems is a critical mechanism of late-life depression. Accordingly, it uses “reward exposure”...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of geriatric psychiatry 2016-04, Vol.24 (4), p.320-326
Hauptverfasser: Alexopoulos, George S., M.D, Raue, Patrick J., Ph.D, Gunning, Faith, Ph.D, Kiosses, Dimitris N., Ph.D, Kanellopoulos, Dora, Ph.D, Pollari, Cristina, M.P.H, Banerjee, Samprit, Ph.D, Arean, Patricia A., Ph.D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective Engage is a treatment for late-life depression developed to match the skills of community clinicians based on the theory that dysfunction in the Research Domain Criteria Project positive valence systems is a critical mechanism of late-life depression. Accordingly, it uses “reward exposure” (engagement in meaningful, rewarding activities) as its principal intervention. This study tests the hypothesis that change in behavioral activation, an index of positive valence systems function, during successive treatment periods with Engage and during follow-up predicts depression at the end of each period. Methods Forty-eight nondemented, older adults with unipolar major depression were treated openly with 9 weekly sessions of Engage and assessed 36 weeks after entry. Depression severity was assessed with the 24-item Hamilton Depression Rating Scale (HAM-D) and behavioral activation with the Behavioral Activation for Depression Scale (BADS) at baseline, 6 weeks (mid-treatment), 9 weeks (end of treatment), and 36 weeks. Results A mixed-effects model examined whether change in BADS in successive periods occurring during Engage treatment and during follow-up predicts depression at the end of each period. Both BADS change (F1,52  = 18.63, p 
ISSN:1064-7481
1545-7214
DOI:10.1016/j.jagp.2015.11.006